according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Betamethasone / Salicylic Acid Ointment Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS

EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

215-631-6999

## **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Serious eye damage, Category 1 H318: Causes serious eye damage. Reproductive toxicity, Category 1B H360D: May damage the unborn child.

Specific target organ toxicity - repeated H372: Causes damage to organs through pro-

exposure, Category 1 longed or repeated exposure.

Long-term (chronic) aquatic hazard, Cat-H410: Very toxic to aquatic life with long lasting

egory 1 effects.

## 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :





Signal word : Danger

Hazard statements : H318 Causes serious eye damage.

H360D May damage the unborn child.

H372 Causes damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a

POISON CENTER/ doctor.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Hazardous components which must be listed on the label:

salicylic acid betamethasone

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

## Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Paraffin oil	8012-95-1	Asp. Tox. 1; H304	10
	232-384-2	Aquatic Chronic 4;	
		H413	
salicylic acid	69-72-7	Acute Tox. 4; H302	3
	200-712-3	Acute Tox. 2; H330	
	607-732-00-5	Acute Tox. 4; H312	
		Skin Irrit. 2; H315	
		Eye Dam. 1; H318	

according to Regulation (EC) No. 1907/2006



# **Betamethasone / Salicylic Acid Ointment For**mulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

		Repr. 2; H361d	
betamethasone	378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) Aquatic Chronic 1; H410	0,064
		M-Factor (Chronic aquatic toxicity):  1.000  specific concentration limit STOT RE 1; H372 >= 0,01 % Repr. 1B; H360D >= 0,01 %	

For explanation of abbreviations see section 16.

## **SECTION 4: First aid measures**

## 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention immediately.

according to Regulation (EC) No. 1907/2006



# **Betamethasone / Salicylic Acid Ointment For**mulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks Causes serious eye damage.

May damage the unborn child.

Causes damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

## **SECTION 5: Firefighting measures**

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

## 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## **SECTION 7: Handling and storage**

## 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust, fume, gas, mist, vapours or spray.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

according to Regulation (EC) No. 1907/2006



# **Betamethasone / Salicylic Acid Ointment For**mulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

use of administrative controls.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents Organic peroxides Explosives

Gases

7.3 Specific end use(s)

Specific use(s) : No data available

No data available

## **SECTION 8: Exposure controls/personal protection**

## 8.1 Control parameters

## **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Petrolatum	8009-03-8	TWA (Vapour)	50 mg/m3	FOR-2011-
				12-06-1358
		TWA (Mist and	1 mg/m3	FOR-2011-
		particles)		12-06-1358
Paraffin oil	8012-95-1	TWA (Vapour)	50 mg/m3	FOR-2011-
				12-06-1358
		TWA (Mist and	1 mg/m3	FOR-2011-
		particles)		12-06-1358
salicylic acid	69-72-7	TWA	100 μg/m3 (OEB 2)	Internal
	Further information: DSEN			
		Wipe limit	100 μg/100 cm2	Internal
betamethasone	378-44-9	TWA	1 μg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 μg/100 cm <sup>2</sup>	Internal

## Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Paraffin oil	Workers	Inhalation	Long-term systemic effects	5 mg/m3
	Workers	Inhalation	Short-term exposure	5 mg/m3
	Workers	Inhalation	Long-term local ef- fects	5 mg/m3
	Workers	Inhalation	Acute local effects	5 mg/m3

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 09.04.2021 1884766-00012 Date of first issue: 21.08.2017 3.7

#### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9,33 mg/kg food

#### 8.2 Exposure controls

#### **Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure,

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

#### Personal protective equipment

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material Chemical-resistant gloves

Remarks Consider double gloving.

Work uniform or laboratory coat. Skin and body protection

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to NS EN 14387 Combined particulates and organic vapour type (A-P)

Filter type

## **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Physical state ointment

Colour white, translucent Odour No data available Odour Threshold No data available

Melting point/freezing point : No data available

Initial boiling point and boiling : No data available

range

according to Regulation (EC) No. 1907/2006



# **Betamethasone / Salicylic Acid Ointment For**mulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature

Decomposition tempera-

ture

No data available

pH : 4,6 - 5,3

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Vapour pressure

: No data available

No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

according to Regulation (EC) No. 1907/2006



# **Betamethasone / Salicylic Acid Ointment For**mulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

## **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

#### **SECTION 11: Toxicological information**

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Skin contact

exposure Ingestion

Eye contact

#### **Acute toxicity**

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Components:

Paraffin oil:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Assessment: The substance or mixture has no acute dermal

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

toxicity

salicylic acid:

Acute oral toxicity : LD50 (Mouse): 480 mg/kg

LD50 (Rat): 891 mg/kg

LD50 (Rabbit): 1.300 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0,9 mg/l

Exposure time: 1 h

Acute dermal toxicity : LD50 (Rat): 2.000 mg/kg

LD50 (Rabbit): 10.000 mg/kg

betamethasone:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 4.500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0,4 mg/l

Exposure time: 4 h

#### Skin corrosion/irritation

Not classified based on available information.

Components:

Paraffin oil:

Species : Rabbit

Result : No skin irritation

salicylic acid:

Result : Skin irritation

betamethasone:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

**Components:** 

Paraffin oil:

Species : Rabbit

Result : No eye irritation

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

salicylic acid:

Species : Rabbit

Remarks : Severe eye irritation

betamethasone:

Species : Rabbit

Result : No eye irritation

## Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### **Components:**

## salicylic acid:

Test Type : Local lymph node assay (LLNA)

Species : Mouse Result : negative

#### betamethasone:

Exposure routes : Dermal
Species : Guinea pig
Result : Weak sensitizer

#### Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

#### salicylic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mammalian bone marrow sister chromatid ex-

change

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Test Type: Sister chromatid exchange analysis in spermato-

gonia

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

## betamethasone:

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay)
Species: Mouse
Application Route: Oral
Result: equivocal

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

## salicylic acid:

Species: MouseApplication Route: Skin contactExposure time: 1 YearsNOAEL: 2 mg/cm2Result: negative

#### Reproductive toxicity

May damage the unborn child.

#### **Components:**

#### salicylic acid:

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 380 mg/kg body weight Result: Maternal toxicity observed., Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rat

**Application Route: Oral** 

Developmental Toxicity: NOAEL: 80 mg/kg body weight

Result: No effects on foetal development

Reproductive toxicity - As-

sessment

Suspected of damaging the unborn child.

#### betamethasone:

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

Effects on foetal develop-

ment

Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 0,05 mg/kg body weight Result: Fetotoxicity, Malformations were observed.

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 0,42 mg/kg body weight

Result: Malformations were observed.

Species: Mouse

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 1 mg/kg body weight

Result: Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

## **Components:**

## betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood,

Adrenal gland

Assessment : Causes damage to organs through prolonged or repeated

exposure.

## Repeated dose toxicity

## **Components:**

#### Paraffin oil:

Species : Rat, female LOAEL : 161 mg/kg Application Route : Ingestion Exposure time : 90 Days

## salicylic acid:

Species : Rat
NOAEL : 50 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

Species : Rat
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 3 d

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

Target Organs : Liver

betamethasone:

Species : Rabbit
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 10 - 30 d

Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Mouse
LOAEL : 0.1 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Dog LOAEL : 0,05 mg/kg Application Route : Oral

Exposure time : 28 d

Target Organs : Blood, thymus gland, Adrenal gland

#### **Aspiration toxicity**

Not classified based on available information.

#### **Components:**

#### Paraffin oil:

The substance or mixture is known to cause human aspiration toxicity hazards or has to be regarded as if it causes a human aspiration toxicity hazard.

#### 11.2 Information on other hazards

## **Endocrine disrupting properties**

## **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

#### **Experience with human exposure**

**Components:** 

salicylic acid:

Skin contact : Symptoms: Skin irritation Eye contact : Symptoms: Severe irritation

Ingestion : Symptoms: Gastrointestinal discomfort, hearing loss, Dizzi-

ness, electrolyte imbalance

betamethasone:

Inhalation : Target Organs: Adrenal gland

Skin contact : Symptoms: Redness, pruritis, Irritation

#### **SECTION 12: Ecological information**

## 12.1 Toxicity

#### **Components:**

Paraffin oil:

Toxicity to fish : LL50 (Scophthalmus maximus (turbot)): > 100 mg/l

Exposure time: 96 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Acartia tonsa): > 100 mg/l

Exposure time: 48 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

EL50 (Skeletonema costatum (marine diatom)): > 100 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

NOELR (Skeletonema costatum (marine diatom)): > 1 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

salicylic acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 1.380 mg/l

Exposure time: 96 h

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 870 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

: EC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 10 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

betamethasone:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): > 50 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,052 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

NOEC: 0,07 μg/l Exposure time: 219 d

Species: Oryzias latipes (Japanese medaka)

Method: OECD Test Guideline 229

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 8 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

1.000

## 12.2 Persistence and degradability

No data available

#### 12.3 Bioaccumulative potential

#### **Components:**

Paraffin oil:

Partition coefficient: nlog Pow: > 4

octanol/water Remarks: Calculation

salicylic acid:

Partition coefficient: nlog Pow: 2,25

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

octanol/water

betamethasone:

Partition coefficient: n-

octanol/water

log Pow: 2,11

## 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

**Product:** 

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

#### 12.6 Other adverse effects

**Product:** 

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

#### 14.2 UN proper shipping name

according to Regulation (EC) No. 1907/2006



# **Betamethasone / Salicylic Acid Ointment For**mulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

**IATA** : Environmentally hazardous substance, solid, n.o.s.

(betamethasone)

14.3 Transport hazard class(es)

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

**ADN** 

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**IMDG** 

Packing group : III Labels : 9

EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

aircraft)

Packing instruction (LQ) : Y956 Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 956

ger aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

**ADN** 

Environmentally hazardous : yes

**ADR** 

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

**IMDG** 

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

#### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

#### **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

preparations and articles (Annex XVII)

REACH - Candidate List of Substances of Very High : Not applicable

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de- : Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

Regulation (EC) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2
E1 ENVIRONMENTAL 100 t 200 t

HAZARDS

## Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

## The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H302 : Harmful if swallowed.

H304 : May be fatal if swallowed and enters airways.

H312 : Harmful in contact with skin. H315 : Causes skin irritation.

H318 : Causes serious eye damage.

H330 : Fatal if inhaled.

H360D : May damage the unborn child.

H361d : Suspected of damaging the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H410 : Very toxic to aquatic life with long lasting effects.
H413 : May cause long lasting harmful effects to aquatic life.

#### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aguatic Chronic : Long-term (chronic) aguatic hazard

Asp. Tox. : Aspiration hazard Eye Dam. : Serious eye damage Repr. : Reproductive toxicity

according to Regulation (EC) No. 1907/2006



# Betamethasone / Salicylic Acid Ointment Formulation

Version **Revision Date:** SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

Skin Irrit. Skin irritation

Specific target organ toxicity - repeated exposure STOT RE

Norway. Occupational Exposure limits FOR-2011-12-06-1358

Long term exposure limit FOR-2011-12-06-1358 /

**TWA** 

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice: IARC - International Agency for Research on Cancer: IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA -Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods: vPvB - Very Persistent and Very Bioaccumulative

## **Further information**

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

#### Classification of the mixture:

#### Classification procedure: Eve Dam. 1 H318 Calculation method Repr. 1B H360D Calculation method STOT RE 1 H372 Calculation method Aquatic Chronic 1 H410 Calculation method

according to Regulation (EC) No. 1907/2006



# **Betamethasone / Salicylic Acid Ointment For**mulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.7 09.04.2021 1884766-00012 Date of first issue: 21.08.2017

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN